Capital expenditure · 2019–2025
Beam Therapeutics capital expenditure
$14.9M+67.1% · FY2025
Beam Therapeutics (BEAM) reported $14.9M in capital expenditure for fiscal 2025, +67.1% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $14.9M | +67.1% | Open → |
| FY20242024-12-31 | $8.9M | −73.5% | Open → |
| FY20232023-12-31 | $33.7M | −31.1% | Open → |
| FY20222022-12-31 | $49.0M | +4.6% | Open → |
| FY20212021-12-31 | $46.8M | +186.2% | Open → |
| FY20202020-12-31 | $16.4M | +30.7% | Open → |
| FY20192019-12-31 | $12.5M | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2019–2025 compound annual growth +3.0%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Beam Therapeutics capital expenditure |url=https://companiesranked.com/en/company/beam-therapeutics/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Beam Therapeutics capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/beam-therapeutics/capital-expenditureBibTeX
@misc{companiesranked-en-company-beam-therapeutics-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Beam Therapeutics capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/beam-therapeutics/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-065194 · February 24, 2026
{{cite web |title=Beam Therapeutics capital expenditure — 10-K (0001193125-26-065194) |url=https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.